


RLA-5331

Cat. No.:	HY-152520
Molecular Formula:	C ₄₀ H ₄₃ F ₃ N ₆ O ₇ S
Molecular Weight:	808.87
Target:	Androgen Receptor
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	RLA-5331 is an iron activator containing anti-androgen. RLA-5331 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line ^[1] .								
In Vitro	<p>RLA-5331 (compound 12) (5 μM; 0-6 d) shows inhibitory for VCaP, PC3, LNCaP and C4-2B cells proliferation^[1]. RLA-5331 (5 μM; 24 h) down-regulates the expression level of KLK-2 and KLK-3 in LNCaP cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>VCaP, PC3, LNCaP and C4-2B cells.</td> </tr> <tr> <td>Concentration:</td> <td>5 μM.</td> </tr> <tr> <td>Incubation Time:</td> <td>0-6 d.</td> </tr> <tr> <td>Result:</td> <td>Showed antiproliferative effect.</td> </tr> </table>	Cell Line:	VCaP, PC3, LNCaP and C4-2B cells.	Concentration:	5 μM.	Incubation Time:	0-6 d.	Result:	Showed antiproliferative effect.
Cell Line:	VCaP, PC3, LNCaP and C4-2B cells.								
Concentration:	5 μM.								
Incubation Time:	0-6 d.								
Result:	Showed antiproliferative effect.								

REFERENCES

[1]. Gonciarz RL, et al. Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. Eur J Med Chem. 2023 Jan 14;249:115110.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA